Targeting Mitochondria Congress 2018 will be held in Berlin in October 23-25, 2018
The Scientific Committee of the World Mitochondria Society is under preparation of the 9th World Congress on Targeting Mitochondria which will be held in Berlin on October 23-25, 2018.
All the information will be added on this website soon.
If you are interested to receive all the information about the World Mitochondria Society and Targeting Mitochondria 2018, please subscribe to WMS newsletter by clicking here.
Source for picture: Flixbus
Cellomics of mitochondrial morphofunction: presentation of the recent advances
During the 9th World Congress on Targeting Mitochondria 2018 which will be held in Berlin next October 23-25, Prof. Werner Koopman from RadboudUMC University, Nijmegen, The Netherlands will present a strategic talk about Cellomics of mitochondrial morphofunction.
According to Prof Koopman: "Mutations in NADH:ubiquinone oxidoreductase (complex I or CI), the first complex of the mitochondrial oxidative phosphorylation (OXPHOS) system, induce Leigh syndrome (LS) leading to early death in children. The LS pathomechanism is still poorly understood and effective treatment options are still lacking. Here we applied high content microscopy analysis (cellomics) to investigate the hypothesis that LS fibroblasts display “reductive stress” and that this stress impacts on cell viability and bioenergetics."
If you would like to know more about Targeting Mitochondria Congress: www.targeting-mitochondria.com
Targeting mitochondrial metabolism, geroprotection to treating Alzheimer’s disease
Dr. Antonio Currais from The Salk Institute for Biological Studies, La Jolla, USA will give a presentation about "Targeting mitochondrial metabolism, geroprotection to treating Alzheimer’s disease" during the 9th World Congress on Targeting Mitochondria, which will be held at Steigenberger Hotel, Berlin on October 23-25, 2018.
According to Dr Currais: "In light of the consistent failures in clinical trials for Alzheimer's disease (AD), there is an urgent need to understand the primary mechanisms driving the disease and to identify new drug targets based upon this information. Age is by far the greatest risk factor for AD and related dementias. Using a set of compounds that we developed to purposely target features of the aging brain, we have identified a unique anti-aging and neuroprotective molecular pathway that is associated with the enhancement of mitochondrial metabolism and stability over time. The implications of our findings to the fields of aging, AD and mitochondria will be presented and discussed."
For more information, please visit www.targeting-mitochondria.com
Modulation of cytochrome C oxidase activity to attenuate brain ischemia/reperfusion injury
Prof. Maik Hüttemann from the Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, USA will give a presentation entitled “Therapeutic application of specific near-infrared light wavelengths that inhibit cytochrome c oxidase results in robust neuroprotection” during the 9th World Congress on Targeting Mitochondria, which will be held at Steigenberger Hotel, Berlin on October 23-25, 2018.His research focuses cytochrome c oxidase (COX) and the small electron carrier cytochrome c (Cytc), which together catalyze the terminal reaction of the electron transport chain. His group studies basic processes, such as cell signaling pathways that act on COX and Cytc, which are often dysregulated in human diseases and under cellular stress conditions. His translational interest is geared toward the development of a new and non-invasive technology for the treatment of ischemia-reperfusion injury using infrared light.
The legal framework for mitochondrial therapy will be presented during Targeting Mitochondria Congress
Dr. Timo Faltus from the Martin-Luther-University Halle-Wittenberg, Germany will give a presentation entitled “The legal framework for mitochondrial therapy : Identifying and preventing legal pitfalls within the translation from bench to bedside” during the 9th World Congress on Targeting Mitochondria, which will be held at Steigenberger Hotel, Berlin on October 23-25, 2018.
According to Dr. Timo Faltus: "The therapeutic implementation of the various approaches of mitochondrial therapy is, irrespective of the therapeutic options, in the European Union and especially in Germany legally problematic. Certain versions of mitochondrial therapy may even be legally prohibited. These legal uncertainties and hurdles put successful translation of mitochondrial therapy at risk overall. Therefore, scientists should consider the issues of lawful development of mitochondrial therapy timely. The presentation will give an overview on the various legal questions of mitochondrial therapy from bench to bedside and will make scientists aware of legal pitfalls, to promote a successful translation of mitochondrial therapy".
Dr. Timo Faltus holds an Diploma of Biology (equivalent to a Master's degree) and a Diploma of Law, both from Goethe University Frankfurt, Germany. He also holds a doctorate of laws from Martin-Luther-University Halle-Wittenberg, Germany.
Currently, Timo leads the interdisciplinary research project GenomELECTION, which i.a. is concerned with the legal issues of genome editing. In addition, he collaborates with several research projects that develop cell-based therapies for various indications. In particular, Timo has specialized in regulatory issues of cell therapy, gene therapy, point-of-care therapy, and the use of medical devices to manufacture cell-derived pharmaceuticals within medical practices and hospitals.
For more information about Targeting Mitochondria 2018, please visit www.targeting-mitochondria.com
How to utilize a human hepatoma cell line to study off-target effects of drugs on mitochondrial DNA maintenance and bioenergetics?
The next 9th World Congress on Targeting Mitochondria, will welcome Dr Matthew J. Young from SIU School of Medicine in Carbondale, USA to talk about “Utilizing a human hepatoma cell line to study off-target effects of drugs on mitochondrial DNA maintenance and bioenergetics”.
According to Dr Young: "Evidence suggests anti-HIV nucleoside reverse transcriptase inhibitors (NRTIs) block the DNA synthesis activity of human DNA polymerases localized to mitochondria. Mitochondrial DNA (mtDNA) maintenance is important as mtDNA damage can induce cell death. Recently, NRTI drugs have been proposed to have anti-cancer properties. We are currently using a human hepatoma-derived cell line to investigate effects of drugs on cellular viability, bioenergetics, and mtDNA maintenance”.
Targeting Mitochondria 2018
October 23-25, 2018 - Berlin, Germany
www.targeting-mitochondria.com
Metabolic switches saving mitochondria from oxidative stress
Prof. Carsten Culmsee from Universität Marburg, Marburg, Germany will participate again in the Targeting Mitochindria 2018 congress and will talk about "Metabolic switches saving mitochondria from oxidative stress".
During the congress, Prof. Culmsee will present several examples of pharmacological and genetic approaches inducing bioenergetic switches from mitochondrial respiration to glycolysis which increase mitochondrial and cellular resilience against oxidative stresswith relevance to human diseases involving neurodegeneration and neuroinflammation.
For more information about Targeting Mitochondria 2018, please visit www.targeting-mitochondria.com
The mitochondrial link to cocaine addiction: recent scientific advances
Mary Kay Lobo from University of Maryland School of Medicine, Baltimore, USA will talk about "The mitochondrial link to cocaine addiction: recent scientific advances" during the 9th World Congress on Targeting Mitochondria 2018 which will be held in Berlin next October 23-25.
If you would like to know more about Targeting Mitochondria Congress: www.targeting-mitochondria.com
